ZBIO

29.51

1.06% 0.31

Handel nachbörslich: 29.54 0.03 +0.10%

Zenas Biopharma Inc (ZBIO)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

$29.20

Offen:

$28.76

24-Stunden-Volumen:

630.04K

Relative Volume:

0.80

Marktkapitalisierung:

$1.86B

Einnahmen:

$10.00M

Nettoeinkommen (Verlust:

$-425.15M

KGV:

-3.2441

EPS:

-9.0964

Netto-Cashflow:

$-210.48M

1W Leistung:

-9.00%

1M Leistung:

+2.54%

6M Leistung:

+11.78%

1J Leistung:

+76.07%

1-Tages-Spanne:

$28.16

$30.31

1-Wochen-Bereich:

$27.81

$32.97

52-Wochen-Spanne:

$13.50

$44.60

Zenas Biopharma Inc Stock (ZBIO) Company Profile

Firmenname

Zenas Biopharma Inc

Sektor

Healthcare (1080)

Branche

Biotechnology (604)

Telefon

857-271-2954

Adresse

852 WINTER STREET, SUITE 250, WALTHAM

Mitarbeiter

167

Twitter

Nächster Verdiensttermin

2026-08-11

Neueste SEC-Einreichungen

ZBIO's Discussions on Twitter

Compare ZBIO vs VRTX, REGN, ARGX, RVMD, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ZBIO Zenas Biopharma Inc	29.51	1.98B	10.00M	-425.15M	-210.48M	-9.0964
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-05	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2025-03-20	Eingeleitet	Wedbush	Outperform
2025-02-04	Eingeleitet	Wolfe Research	Outperform
2024-12-16	Eingeleitet	H.C. Wainwright	Buy
2024-11-05	Eingeleitet	Rodman & Renshaw	Buy
2024-10-08	Eingeleitet	Citigroup	Buy
2024-10-08	Eingeleitet	Guggenheim	Buy
2024-10-08	Eingeleitet	Jefferies	Buy
2024-10-08	Eingeleitet	Morgan Stanley	Overweight

Alle ansehen

Zenas Biopharma Inc Aktie (ZBIO) Neueste Nachrichten

Aug 15, 2026

Walleye Capital LLC Takes $5.31 Million Position in Zenas BioPharma, Inc. $ZBIO - marketbeat.com

Aug 15, 2026

Aug 14, 2026

Zenas BioPharma's (ZBIO) Buy Rating Reaffirmed at Guggenheim - marketbeat.com

Aug 14, 2026

Zenas BioPharma's (ZBIO) Outperform Rating Reiterated at Wedbush - marketbeat.com

Aug 14, 2026

Zenas BioPharma (ZBIO) Is Down 9.2% After Wider Losses And Leadership ChangesWhat's Changed - simplywall.st

Aug 14, 2026

Zenas BioPharma, Inc. Announces Chief Financial Officer Changes, Effective September 30, 2026 - marketscreener.com

Aug 13, 2026

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 6.6% on Disappointing Earnings - marketbeat.com

Aug 13, 2026

Zenas BioPharma Q2 Results: EPS Misses, Sales Fall 95% - scanx.trade

Aug 13, 2026

Zenas BioPharma, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 13, 2026

Zenas BioPharma's Q2 Net Loss Widens; CFO to Step Down - marketscreener.com

Aug 13, 2026

Earnings Flash (ZBIO) Zenas BioPharma Posts Q2 Loss $1.77 a Share, vs. FactSet Est of $1.12 Loss - marketscreener.com

Aug 13, 2026

Form 8K Zenas Biopharma Inc For: 13 August By Investing.com - Investing.com South Africa

Aug 13, 2026

Zenas BioPharma, Inc. 2026: Revenue $1M, Net income ($111.46M), EPS ($1.77) — 10-Q Summary - TradingView

Aug 13, 2026

Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times

Aug 13, 2026

Earnings Flash (ZBIO) Zenas BioPharma, Inc. Reports Q2 Revenue $1.0M - marketscreener.com

Aug 13, 2026

Zenas BioPharma Reports $111.5 Million Second-Quarter Net Loss - Quiver Quantitative

Aug 13, 2026

Aug 08, 2026

Zenas BioPharma (ZBIO) Holds Gains Above $32 as Bullish Momentum BuildsIndex Put Call - dars.gov.et

Aug 08, 2026

Aug 07, 2026

ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, In - The National Law Review

Aug 07, 2026